Clearmind Medicine announced that its MEAI-based oral drug candidate, CMND-100, has arrived in the U.S. following successful manufacturing, marking a key milestone as the Vancouver-based biotech prepares to initiate its FDA-cleared phase 1/2a clinical trial for the treatment of alcohol use disorder (AUD).
According to Clearmind, the company is on track to launch its first-in-human clinical trial of its 5-Methoxy-2-aminoindane (MEAI)-based candidate, a novel psychoactive aminoindane derivative that exerts euphoric, alcohol-like tipsy experience and reduced desire to consume alcoholic beverages. The drug represents a potential breakthrough in treating AUD — a condition affecting over 28 million adults in the U.S. alone — targeting the reduction of alcohol consumption and cravings through a novel mechanism of action.
The trial will assess CMND-100’s safety and efficacy in reducing alcohol consumption. The study will be conducted at two leading research institutions in the U.S., Yale School of Medicine’s Department of Psychiatry and Johns Hopkins University School of Medicine. The Israeli trial will be conducted at the Israel Medical Center for Addiction located in Ramat Gan, Israel.